info@biomedres.us
+1 (502) 904-2126
One Westbrook Corporate Center, Suite 300, Westchester, IL 60154, USA
Site Map
ISSN: 2574 -1241
ISSN: 2574 -1241
Received: February 01, 2018; Published: February 12, 2018
DOI: 10.26717/BJSTR.2018.02.000754
Keratoconusis a progressiveeye disease, whichdiscloses in adolescence and usuallystabilizes in thefourthorfifthdecadeoflife. Theprogressivethinningofcorneal stroma in which the cornea has a conical shapeleads to high irregular a stigmatism and consequently to a significantvisualacuitydecrease. Anymethod to curethediseasehas beendeveloped up to thisday. Corneal collagen cross-linking (CXL) is the first treatment that halts the progression of keratoconus. Cross-linkingconducted in the early stages of keratoconus allows to stop cornealchangesduring early grade, easier to opticalcorrection. From the times of “Dresden Protocol” until now, multiple variations of the standard procedure technique have been introduced and consistent improvement is still being searched for.Not onlydoesthe study presenttheclassicalmethodof CXL, acceleratedand transepithelial CXL modifications, but thelatestresearchabouttheireffectiveness as well.
Keywords: Corneal cross-linking; CXLl; Accelerated cross-linking; High irradiance; Transepithelial cross-linking; Keratoconus
International Association of Landscape Archaeology, Czech Glass Society, Czech Republic
Department of Chemistry, Semenov Institute of Chemical Physics, USSR Academy of Sciences, Moscow, Russia
Pharmaco-kinetics, dynamics and Drug Metabolism, Touro College of Pharmacy, USA
Professor of Nuclear Medicine, Faculty of Medicine and Surgery, University of Milan, Milan, Italy
Associate Professor at Department of Breast and Thyorid Surgey, Chongqing General Hospital, China
Full Text
PDF
